According to a new EY report 'e-pharma: delivering healthier outcomes', e-pharma players are expected to attain a combined market size of US$2.7 billion by 2023 from about US$360 million currently in the next four years. The key growth driv
Indian pharmaceutical market’s (IPM) secondary sales growth moderated to 8.9% YoY in Mar’19 versus 10% YoY in the previous month. Growth was driven by prices (+4.9% YoY), volumes (+1.5% YoY) and new launches (+2.4% YoY).
The pharmaceutical sector is in a recovery mode and the positive trajectory in earnings growth witnessed in 3QFY19 should also be visible in 4QFY19. Pricing pressure in the US has moderated and new products launched are contributing to growth.
Welchol generic – DRL has gained 9% market share for the product as against a low single-digit share at the end of the previous quarter. Glenmark Pharmaceuticals has also been able to expand its market share to 16% from 10% (at the end of the previous quarter).
This is neither an offer nor a solicitation to purchase or sell securities. The information and views contained on this site are believed to be reliable, but no responsibility (or liability) is accepted for errors of fact or opinion. Writers and contributors may be trading in, or have positions in the securities mentioned in their articles. Neither IndiaNotes nor any of the contributors accepts any liability arising out of use of the above information/article. Reproduction in whole or in part without written permission is prohibited.